| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 77.01 mm | 77.01 mm | 77.01 mm | 77.01 mm | 77.01 mm | 77.01 mm |
| Cash burn (monthly) | (no burn) | 2.07 mm | 5.63 mm | 3.81 mm | 6.52 mm | 3.21 mm |
| Cash used (since last report) | n/a | 11.15 mm | 30.35 mm | 20.53 mm | 35.14 mm | 17.28 mm |
| Cash remaining | n/a | 65.87 mm | 46.66 mm | 56.49 mm | 41.87 mm | 59.73 mm |
| Runway (months of cash) | n/a | 31.8 | 8.3 | 14.8 | 6.4 | 18.6 |
| 13F holders | Current |
|---|---|
| Total holders | 65 |
| Opened positions | 12 |
| Closed positions | 31 |
| Increased positions | 15 |
| Reduced positions | 19 |
| 13F shares | Current |
|---|---|
| Total value | 53.41 bn |
| Total shares | 24.25 mm |
| Total puts | 157.40 k |
| Total calls | 74.34 k |
| Total put/call ratio | 2.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Point72 Asset Management | 2.39 mm | $6.63 bn |
| New Enterprise Associates 13 | 2.00 mm | $0.00 |
| NEA Management | 2.00 mm | $5.54 bn |
| KPCB Pandemic & Bio Defense Fund | 1.90 mm | $0.00 |
| Blue Owl Capital | 1.67 mm | $4.64 bn |
| Baker Bros. Advisors | 1.38 mm | $3.83 bn |
| Alyeska Investment | 1.38 mm | $3.82 bn |
| Citadel Advisors | 1.22 mm | $3.37 bn |
| Vanguard | 1.05 mm | $2.90 bn |
| BlackRock | 952.59 k | $2.64 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 Feb 25 | Thierry Chauche | Series A Common Stock | Grant | Acquire A | No | No | 0 | 17,000 | 0.00 | 17,000 |
| 6 Feb 25 | Thierry Chauche | Stock Option Series A Common Stock | Grant | Acquire A | No | No | 4.71 | 69,000 | 324.99 k | 69,000 |
| 6 Feb 25 | Elizabeth Rozek | Series A Common Stock | Grant | Acquire A | No | No | 0 | 34,000 | 0.00 | 194,506 |
| 6 Feb 25 | Elizabeth Rozek | Stock Option Series A Common Stock | Grant | Acquire A | No | No | 4.71 | 138,000 | 649.98 k | 138,000 |
| 6 Feb 25 | Eduardo Bruno Martins | Series A Common Stock | Grant | Acquire A | No | No | 0 | 34,000 | 0.00 | 115,213 |
| 6 Feb 25 | Eduardo Bruno Martins | Stock Option Series A Common Stock | Grant | Acquire A | No | No | 4.71 | 138,000 | 649.98 k | 138,000 |
| 6 Feb 25 | David Happel | Series A Common Stock | Grant | Acquire A | No | No | 0 | 116,000 | 0.00 | 755,200 |
| 6 Feb 25 | David Happel | Stock Option Series A Common Stock | Grant | Acquire A | No | No | 4.71 | 472,000 | 2.22 mm | 472,000 |
